Splenectomy prior to antiviral therapy in patients with hepatitis C virus related decompensated cirrhosis

Brazilian Journal of Infectious Diseases

Volumn 17, Issue 5, 2013, Pages 601-605

  Ji, Fanpu ^a   Zhang, Shu ^a   Huang, Na ^a   Deng, Hong ^a   Li, Zongfang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Antiviral therapy; Hepatitis C virus; Splenectomy; Thrombocytopenia

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; BILIRUBIN; BIOLOGICAL MARKER; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTHROMBIN; RIBAVIRIN; WARFARIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ASCITES; BACTERIAL PERITONITIS; CHILD PUGH SCORE; CLINICAL ARTICLE; CLINICAL TRIAL; DECOMPENSATED LIVER CIRRHOSIS; DRUG DOSE REDUCTION; DRUG RESPONSE; ECHOGRAPHY; ETHNICITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS RELATED DECOMPENSATED CIRRHOSIS; HUMAN; HUMAN TISSUE; HYPERSPLENISM; LEUKOCYTE COUNT; LIVER FUNCTION; MALE; NEUTROPHIL COUNT; OPEN SPLENECTOMY WITH AZYGOPORTAL DISCONNECTION; PATIENT COMPLIANCE; PORTAL VEIN THROMBOSIS; POSTOPERATIVE COMPLICATION; PROTHROMBIN TIME; SPLENECTOMY; SPLENOMEGALY; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTE COUNT;

ANTIVIRAL THERAPY; HEPATITIS C VIRUS; SPLENECTOMY; THROMBOCYTOPENIA;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIBAVIRIN; SPLENECTOMY; TREATMENT OUTCOME;

EID: 84884729816     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2013.02.004     Document Type: Article

References (20)

1. Lauer G.M., Walker B.D. Hepatitis C virus infection. N Engl J Med 2001, 345:41-52.
2. Ferreira Sda C., Carneiro Mde V., Souza F.F., et al. Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon. Braz J Infect Dis 2010, 14:330-334.
3. Cheinquer N., Cheinquer H., Wolff F.H., Coelho-Borges S. Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis. Braz J Infect Dis 2010, 14:457-461.
4. Iacobellis A., Siciliano M., Perri F., et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007, 46:206-212.
5. Ji F.P., Li Z.X., Cai Z.F., et al. Short-term efficacy and safety of standard interferon with a low accelerating dosage regimen in HCV-related decompensated cirrhosis. Zhonghua Gan Zang Bing Za Zhi 2010, 18:946-948.
6. Davis G.L., Albright J.E., Cook S.F., Rosenberg D.M. Projecting future complications of Chronic hepatitis C in the United States. Liver Transpl 2003, 9:331-338.
7. Iacobellis A., Perri F., Valvano M.R., Caruso N., Niro G.A., Andriulli A. Long-term. outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol 2011, 9:249-253.
8. Lok A.S., Gardiner D.F., Lawitz E., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012, 366:216-224.
9. Akahoshi T., Tomikawa M., Korenaga D., Ikejiri K., Saku M., Takenaka K. Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism. Surg Endosc 2010, 24:680-685.
10. Ikezawa K., Naito M., Yumiba T., et al. Splenectomy and antiviral treatment for thrombocytopenic patients with chronic hepatitis C virus infection. J Viral Hepat 2010, 17:488-492.
11. Li Z.F., Wang B.T., Zhang S., et al. Therapeutic effects of linear stapler pericardial devascularization on portal hypertension: analysis of 52 cases. J Surg Concepts Pract 2009, 14:18-20.
12. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374. American Association for the Study of Liver Diseases. AASLD Practice Guidelines.
13. Vigani A.G., Gonçales E.S., Pavan M.H., et al. Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3. Braz J Infect Dis 2012, 16:232-236.
14. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
15. Sekiguchi T., Nagamine T., Takagi H., Mori M. Reduction of virus burden-induced splenectomy in patients with liver cirrhosis related to hepatitis C virus infection. World J Gastroenterol 2006, 12:2089-2094.
16. + T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis. Clin Exp Immunol 2011, 165:243-250.
17. Muir A.J., Hu K.Q., Gordon S.C., et al. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hepat 2011, 18:134-143.
18. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
19. Yu M.L., Huang C.F., Huang J.F., et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011, 53:7-13.
20. Bourlière M., Khaloun A., Wartelle-Bladou C., et al. Future treatment of patients with HCV cirrhosis. Liver Int 2012, 32(Suppl. 1):113-119.